Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: human insulin Clear all
Active, not recruiting Phase 4 Interventional

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435
View directory record Official record
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

NCT04585776
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
LY900014, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • West Des Moines, Iowa • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Sep 25, 2026, 11:06 PM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Not applicable Interventional Results available

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

NCT00413335
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
10 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 25, 2026, 11:06 PM EDT
Terminated No phase listed Observational

Genetics and Clinical Characteristics of Bardet-Biedl Syndrome

NCT00078091
View directory record Official record
Conditions
Bardet-Biedl Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Not applicable Interventional

Hybrid Closed Loop in High Risk Youth With Type 1 Diabetes

NCT04807374
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Control IQ
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

NCT05352815
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
IcoSema, Insulin icodec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
110
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 25, 2026, 11:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
View directory record Official record
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 25, 2026, 11:06 PM EDT
Withdrawn Not applicable Interventional

Reversibility of Brain Glucose Transport and Metabolism in T2DM: an Intervention Study

NCT04283617
View directory record Official record
Conditions
Diabete Type 2
Interventions
Intensification of insulin regimen/Nutrition
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Not applicable Interventional

FL3X Study: An Adaptive Intervention to Improve Outcomes for Youth With Type 1 Diabetes (FL3X)

NCT01286350
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
FL3X: Flexible Lifestyle Empowering Change
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years to 16 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Aurora, Colorado • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

NCT02670915
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart, insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Weight Loss on Hepatic and Muscle Lipid Content and on Insulin Sensitivity on Obese Adolescents With NAFLD

NCT00585299
View directory record Official record
Conditions
Fatty Liver, Insulin Resistance
Interventions
Low-fat diet, Traditional diet
Other
Lead sponsor
Yale University
Other
Eligibility
10 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Not applicable Interventional Results available

Control-IQ Technology in Individuals With Type 2 Diabetes

NCT05111301
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Control-IQ technology 1.5
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

Tandem Predictive Low Glucose Suspend Inpatient Feasibility Study

NCT02877771
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Insulin Pump
Interventions
t:slim insulin pump with predictive low glucose suspend
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Not applicable Interventional Results available

SPECS: Safe Pediatric Euglycemia in Cardiac Surgery

NCT00443599
View directory record Official record
Conditions
Heart Defects, Congenital, Hyperglycemia
Interventions
Insulin, Usual Care
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 36 Months
Enrollment
989 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Sep 25, 2026, 11:06 PM EDT
Recruiting Phase 2 Interventional

Tirzepatide for Treatment of CCCA

NCT07734870
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Tirzepatide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 25, 2026, 11:06 PM EDT
Completed No phase listed Observational

Coagulation and Fibrinolysis in Pediatric Insulin Titration Trial (CAF-PINT)

NCT01892969
View directory record Official record
Conditions
Heart Failure, Respiratory Failure
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
14 Days to 18 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Los Angeles, California • Oakland, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

NCT00170937
View directory record Official record
Conditions
METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION
Interventions
valsartan plus hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

NCT00577577
View directory record Official record
Conditions
Myotonic Dystrophy Type 1
Interventions
rhIGF-I/rhIGFBP-3, placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
21 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Orange, California • Sacramento, California • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fatty Acid Oxidation Defects and Insulin Sensitivity

NCT02517307
View directory record Official record
Conditions
Very Long-chain Acyl-CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Normal Volunteers, Carnitine Palmitoyltransferase II Deficiency, Myopathic
Interventions
Intralipid/Heparin, Glycerol/Saline, Hyperinsulinemic euglycemic clamp
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 25, 2026, 11:06 PM EDT
Terminated Not applicable Interventional

Step Down Colon Cancer Risk

NCT01476631
View directory record Official record
Conditions
Adenomatous Polyps
Interventions
Walking
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 4, 2013 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

NCT01533181
View directory record Official record
Conditions
Recurrent Small Cell Lung Carcinoma
Interventions
Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study, Topotecan Hydrochloride
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 25, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

NCT04763265
View directory record Official record
Conditions
Frown Lines
Interventions
Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"
Biological
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Santa Monica, California • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 25, 2026, 11:06 PM EDT
Active, not recruiting Phase 3 Interventional

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

NCT06625411
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
VRDN-003, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 25, 2026, 11:06 PM EDT